| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 155 | 169 | 172 | 174 | 182 | 187 | 205 | 193 | 206 | 242 | 246 | 259 | 203 | 258 | 238 | 257 | 222 | 294 | 270 | 415 | 365 | 421 | 395 | 390 | 465 | 315 | 458 | 336 |
| Expenses | 145 | 154 | 156 | 154 | 162 | 161 | 176 | 162 | 172 | 201 | 199 | 219 | 175 | 215 | 204 | 217 | 193 | 224 | 215 | 287 | 266 | 280 | 272 | 278 | 316 | 249 | 311 | 277 |
| EBITDA | 10 | 15 | 16 | 20 | 19 | 26 | 29 | 32 | 35 | 42 | 47 | 40 | 28 | 43 | 34 | 40 | 29 | 70 | 55 | 128 | 99 | 141 | 123 | 112 | 149 | 67 | 146 | 59 |
| Operating Profit % | 6 % | 9 % | 9 % | 11 % | 10 % | 13 % | 14 % | 16 % | 16 % | 17 % | 19 % | 10 % | 13 % | 17 % | 14 % | 15 % | 13 % | 24 % | 20 % | 29 % | 27 % | 33 % | 31 % | 28 % | 28 % | 20 % | 22 % | 16 % |
| Depreciation | 6 | 6 | 7 | 7 | 8 | 8 | 8 | 8 | 9 | 9 | 10 | 11 | 12 | 12 | 13 | 12 | 13 | 13 | 13 | 14 | 14 | 15 | 15 | 17 | 16 | 16 | 16 | 17 |
| Interest | 4 | 4 | 3 | 5 | 4 | 5 | 6 | 7 | 5 | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 4 | 2 | 4 | 4 | 4 | 3 | 1 | 2 | 2 |
| Profit Before Tax | 1 | 5 | 6 | 8 | 8 | 12 | 16 | 17 | 20 | 29 | 32 | 24 | 12 | 28 | 18 | 24 | 14 | 53 | 39 | 110 | 83 | 122 | 105 | 92 | 130 | 49 | 128 | 39 |
| Tax | 0 | 1 | 1 | 2 | 2 | 4 | 5 | 27 | 5 | 7 | 5 | 7 | 3 | 7 | 5 | 3 | 4 | 15 | 8 | 26 | 21 | 32 | 23 | 25 | 32 | 17 | 26 | 12 |
| Net Profit | 1 | 5 | 5 | 7 | 6 | 9 | 11 | -9 | 15 | 21 | 27 | 17 | 9 | 20 | 13 | 22 | 10 | 39 | 31 | 85 | 62 | 89 | 81 | 68 | 98 | 33 | 102 | 28 |
| EPS in ₹ | 0.44 | 3.55 | 3.66 | 5.17 | 4.45 | 6.77 | 8.66 | -7.25 | 11.82 | 16.71 | 20.84 | 13.48 | 6.81 | 15.88 | 10.08 | 16.97 | 7.77 | 29.97 | 23.81 | 65.90 | 48.23 | 69.56 | 63.44 | 52.66 | 76.28 | 25.60 | 79.18 | 21.67 |
Neuland Laboratories
13,030.00
+1,286.00
(10.95%)
Market Cap
16,717.35 Cr
EPS
233.89
PE Ratio
74.39
Dividend Yield
0.10 %
Industry
Healthcare52 Week High
18,100.00
52 Week Low
6,121.50
PB Ratio
9.90
Debt to Equity
0.10
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,679.20 | #1 4,02,896.33 | 35.21 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 43.89 | |
6,544.50 | 1,73,735.91 | 80.34 | 8,184.00 | 0.89 | 1,600 | 23.05 | 57.72 | |
1,504.20 | 1,21,481.44 | 22.82 | 26,520.70 | 14.17 | 4,155 | 30.28 | 55.17 | |
1,320.90 | 1,10,223.21 | #1 19.03 | 28,905.40 | 12.36 | 5,578 | 21.14 | 80.62 | |
3,154.30 | 1,06,755.85 | 55.19 | 10,785.70 | 11.59 | 1,656 | 10.91 | 44.00 | |
2,352.40 | 97,054.97 | 49.05 | 10,615.60 | 19.57 | 1,942 | -10.91 | 37.92 | |
960.15 | 96,613.56 | 20.59 | 19,831.50 | 13.82 | 3,831 | -0.19 | 71.38 | |
1,999.60 | 91,289.93 | 27.77 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 50.41 | |
1,161.10 | 67,436.88 | 19.49 | 29,559.20 | 17.55 | 3,169 | -0.50 | 47.11 | |
31,630.00 | 67,211.54 | 47.62 | 6,097.20 | 10.80 | 1,201 | 27.83 | 63.13 |
Forecast
Actual
Growth Rate
Revenue Growth
30.83 %
Net Income Growth
83.55 %
Cash Flow Change
10.10 %
ROE
42.19 %
ROCE
47.41 %
EBITDA Margin (Avg.)
28.96 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,384 | 1,580 | 1,833 |
| Fixed Assets | 123 | 139 | 466 | 475 | 542 | 653 | 716 | 767 | 758 | 824 |
| Current Assets | 316 | 314 | 375 | 447 | 454 | 515 | 550 | 581 | 761 | 921 |
| Capital Work in Progress | 42 | 41 | 20 | 126 | 105 | 24 | 17 | 21 | 41 | 46 |
| Investments | 0 | 0 | 8 | 8 | 8 | 8 | 7 | 4 | 1 | 1 |
| Other Assets | 347 | 345 | 393 | 463 | 477 | 547 | 585 | 592 | 781 | 962 |
| Total Liabilities | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,384 | 1,580 | 1,833 |
| Current Liabilities | 295 | 268 | 286 | 367 | 327 | 358 | 369 | 363 | 439 | 428 |
| Non Current Liabilities | 55 | 69 | 54 | 146 | 104 | 163 | 170 | 180 | 147 | 122 |
| Total Equity | 162 | 187 | 546 | 558 | 699 | 710 | 787 | 841 | 994 | 1,283 |
| Reserve & Surplus | 152 | 178 | 537 | 549 | 686 | 697 | 774 | 828 | 981 | 1,270 |
| Share Capital | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 13 | 13 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 0 | 1 | -4 | -0 | 5 | 3 | -9 | 3 | 40 | 42 |
| Investing Activities | -14 | -20 | -42 | -116 | -77 | -49 | -85 | -95 | -61 | -150 |
| Operating Activities | 13 | 45 | 39 | 11 | 70 | 57 | 189 | 60 | 237 | 261 |
| Financing Activities | 1 | -24 | -0 | 105 | 12 | -6 | -114 | 38 | -136 | -69 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 36.22 % | 36.22 % | 36.22 % | 36.22 % | 36.22 % | 36.22 % | 36.22 % | 36.14 % | 36.14 % | 36.03 % | 35.97 % | 32.80 % | 32.74 % | 32.72 % | 32.64 % | 32.68 % | 32.68 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 21.57 % | 22.69 % | 24.44 % | 25.72 % | 26.46 % | 23.86 % | 22.11 % |
| DIIs | 0.87 % | 0.04 % | 0.80 % | 0.80 % | 0.80 % | 0.80 % | 6.58 % | 6.55 % | 7.10 % | 6.76 % | 6.99 % | 6.03 % | 6.54 % | 6.39 % | 6.38 % | 9.08 % | 10.97 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.44 % | 0.46 % | 0.40 % | 0.40 % | 0.40 % | 0.40 % | 0.40 % | 0.40 % | 0.40 % | 0.40 % | 0.40 % |
| Public / Retail | 34.06 % | 36.62 % | 33.19 % | 32.84 % | 32.43 % | 33.25 % | 31.03 % | 30.09 % | 29.86 % | 29.01 % | 27.86 % | 29.51 % | 27.97 % | 27.05 % | 26.50 % | 26.05 % | 25.86 % |
| Others | 28.85 % | 27.12 % | 29.80 % | 30.15 % | 30.56 % | 29.74 % | 25.73 % | 26.76 % | 26.51 % | 27.80 % | 7.21 % | 8.57 % | 7.91 % | 7.71 % | 7.61 % | 7.93 % | 7.99 % |
| No of Share Holders | 0 | 22,412 | 34,978 | 34,332 | 32,426 | 32,257 | 31,976 | 30,600 | 26,948 | 25,223 | 26,824 | 27,723 | 28,616 | 29,077 | 34,567 | 39,315 | 39,333 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 2 | 5 | 5 | 10 | 14 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.1 | 0.49 | 0.28 | 0.16 | 0.12 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 30 Jul 2025 |  Annual General Meeting | NA | 30 Jul 2025 | 12,472.30 | 11,754.20 |
| 15 May 2025 |  Quarterly Result Announcement | NA | 15 May 2025 | 12,820.80 | 12,472.30 |
| 10 Feb 2025 | Quarterly Result Announcement | NA | 10 Feb 2025 | 13,869.35 | 14,247.35 |
| 06 Nov 2024 | Quarterly Result Announcement | NA | 06 Nov 2024 | 16,250.70 | 15,858.20 |
| 31 Jul 2024 | Annual General Meeting | NA | 31 Jul 2024 | 7,146.85 | 9,051.20 |
| 13 Jul 2024 |  Dividend | ₹ 14.00 /share | 12 Jul 2024 | 7,146.85 | 8,094.80 |
| 12 Jul 2023 | Dividend | ₹ 10.00 /share | 11 Jul 2023 | 2,115.25 | 2,998.80 |
| 15 Jul 2022 | Dividend | ₹ 5.00 /share | 14 Jul 2022 | 1,334.25 | 1,298.00 |
| 01 Jul 2021 | Dividend | ₹ 3.00 /share | 29 Jun 2021 | 2,692.70 | 2,142.20 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
May 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 19, 2025
May 19, 2025Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateMay 19, 2025
May 19, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 19, 2025
May 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
May 15, 202541St Annual General Meeting Of The Shareholders Of The Company Is Scheduled To Be Held On Wednesday July 30 2025May 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 15, 2025
May 15, 2025The Record Date For The Purpose Of Determining The Shareholder Eligible To Receive The Final Dividend For The Financial Year Ended March 31 2025 Has Been Fixed As July 18 2025May 15, 2025
May 15, 2025Appointment Of Secretarial Auditors Of The CompanyMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 15, 2025
May 15, 2025Corporate Action-Board approves DividendMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
May 15, 2025Audited Financial Results And Recommendation Of Final Dividend For Financial Year 2024-25May 15, 2025
May 15, 2025Board Meeting Outcome for Audited Financial Results And Recommendation Of Final Dividend For Financial Year 2024-25May 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 05, 2025
May 05, 2025 Intimation Regarding Completion Of US FDA InspectionMay 02, 2025
May 02, 2025Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2025 And; To Recommend Final Dividend If Any For The Financial Year Ended MaApr 24, 2025
Apr 24, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 02, 2025
Apr 02, 2025Closure of Trading WindowMar 25, 2025
Mar 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 19, 2025
Mar 19, 2025Announcement under Regulation 30 (LODR)-Credit RatingMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMar 10, 2025
Mar 10, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 03, 2025
Mar 03, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 03, 2025
Mar 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 27, 2025
Feb 27, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Feb 27, 2025
Feb 27, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 25, 2025
Feb 25, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 25, 2025
Feb 25, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 25, 2025
Feb 25, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 11, 2025
Feb 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 11, 2025
Feb 11, 2025Integrated Filing (Financial)Feb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 10, 2025
Feb 10, 2025Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2024Feb 10, 2025
Feb 10, 2025Board Meeting Outcome for Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2024Feb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 31, 2025
Jan 31, 2025Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2024Jan 23, 2025
Jan 23, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 21, 2025
Jan 21, 2025Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateJan 03, 2025
Jan 03, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 03, 2025
Jan 03, 2025Update On Final Transfer Of Part Of Nanakramguda PropertyDec 13, 2024
Dec 13, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 02, 2024
Dec 02, 2024Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Nov 29, 2024
Nov 29, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 28, 2024
Nov 28, 2024Technical Indicators
RSI(14)
Neutral 51.13
ATR(14)
Less Volatile 441.63
STOCH(9,6)
Neutral 76.14
STOCH RSI(14)
Overbought 95.49
MACD(12,26)
Bullish 69.75
ADX(14)
Weak Trend 12.56
UO(9)
Bearish 49.74
ROC(12)
Uptrend And Accelerating 5.32
WillR(14)
Neutral -28.77
Mutual Fund Holdings
| Funding House | No of Shares | Current Holding % | 1M Change % | 3M Change % | Month | |
|---|---|---|---|---|---|---|
 LIC MF Children's Fund Direct-Growth | 185 | 1.51% | 1.51% | 1.51% | Apr 2025 | |
| LIC MF Small Cap Fund Direct - Growth | 5746 | 1.33% | 1.33% | 1.33% | Apr 2025 | |
 PGIM India Retirement Fund Direct - Growth | 531 | 0.79% | 0.79% | 0.79% | Apr 2025 | |
 ITI Bharat Consumption Fund Direct-Growth | 0 | 0.00% | -0.75% | 0.00% | Apr 2025 | |
| ITI Pharma and Healthcare Fund Direct - Growth | 3601 | 1.97% | -0.31% | -0.06% | Apr 2025 | |
 Bajaj Finserv Healthcare Fund Direct-Growth | 7709 | 2.98% | 0.22% | 0.35% | Apr 2025 | |
 HSBC Small Cap Fund Direct-Growth | 261377 | 2.13% | -0.21% | -0.20% | Apr 2025 | |
| LIC MF Healthcare Fund Direct - Growth | 2184 | 3.11% | -0.18% | 0.00% | Apr 2025 | |
| LIC MF Dividend Yield Fund Direct - Growth | 6750 | 1.59% | 0.18% | 0.48% | Apr 2025 | |
 JM Small Cap Fund Direct - Growth | 13666 | 2.60% | -0.18% | -0.08% | Apr 2025 | |
 Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth | 0 | 0.00% | -0.13% | 0.00% | Apr 2025 | |
| PGIM India Small Cap Fund Direct - Growth | 9869 | 0.85% | 0.12% | 0.16% | Apr 2025 | |
 Mirae Asset Small Cap Fund Direct-Growth | 21778 | 1.88% | 0.09% | -0.01% | Apr 2025 | |
| HSBC Multi Cap Fund Direct - Growth | 56400 | 1.51% | -0.08% | -0.03% | Apr 2025 | |
 Sundaram Small Cap Fund Direct-Growth | 40411 | 1.58% | -0.07% | 0.03% | Apr 2025 | |
| Bajaj Finserv Flexi Cap Fund Direct-Growth | 29334 | 0.78% | -0.07% | -0.03% | Apr 2025 | |
 ICICI Prudential Flexicap Fund Direct - Growth | 187520 | 1.35% | 0.07% | 0.16% | Apr 2025 | |
| PGIM India Healthcare Fund Direct-Growth | 1694 | 1.89% | -0.07% | 0.03% | Apr 2025 | |
| JM Aggressive Hybrid Fund Direct-Growth | 9500 | 1.42% | -0.07% | 0.04% | Apr 2025 | |
 Aditya Birla Sun Life Nifty Smallcap 50 Index Fund Direct-Growth | 2974 | 1.68% | -0.07% | 1.68% | Apr 2025 | |
 WhiteOak Capital Special Opportunities Fund Direct - Growth | 5262 | 0.75% | -0.07% | 0.09% | Apr 2025 | |
 Mahindra Manulife Large & Mid Cap Fund Direct - Growth | 27000 | 1.29% | -0.06% | 0.01% | Apr 2025 | |
 Tata Nifty MidSmall Healthcare Index Fund Direct - Growth | 2099 | 1.87% | 0.06% | 1.87% | Apr 2025 | |
| WhiteOak Capital Pharma and Healthcare Fund Direct - Growth | 4079 | 1.53% | 0.06% | 0.22% | Apr 2025 | |
 Kotak Nifty Smallcap 50 Index Fund Direct - Growth | 1662 | 1.68% | -0.06% | 1.68% | Apr 2025 |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
